EICHORCondition: Major Depressive Disorder · Sponsor: AbbVie
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major depressive disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to placebo treatment. Around 195 adult participant with major depressive disorder will be enrolled in approximately 35 sites in North America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 30-day safety follow-up. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Harmonex /ID# 277517 | Dothan, Alabama, United States | Recruiting |
| Ima Clinical Research Phoenix (Alea) /ID# 277516 | Phoenix, Arizona, United States | Recruiting |
| Preferred Research Partners /ID# 279206 | Little Rock, Arkansas, United States | Recruiting |
| Woodland International Research Group /ID# 277605 | Little Rock, Arkansas, United States | Recruiting |
| Advanced Research Center /ID# 277537 | Anaheim, California, United States | Recruiting |
| Sun Valley Research Center /ID# 277513 | Imperial, California, United States | Recruiting |
| Synergy San Diego /ID# 277553 | Lemon Grove, California, United States | Recruiting |
| Accellacare - Long Beach /ID# 279181 | Long Beach, California, United States | Recruiting |
| CenExel CNR /ID# 277533 | Sherman Oaks, California, United States | Recruiting |
| Inland Psychiatric Medical Group /ID# 279275 | Temecula, California, United States | Recruiting |
| Sunwise Clinical Research /ID# 277555 | Walnut Creek, California, United States | Recruiting |
| CenExel Hollywood FL /ID# 278200 | Hollywood, Florida, United States | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07276997